Biomea Fusion, Inc. has announced a strategic realignment to focus on its core programs in diabetes and obesity, specifically advancing icovamenib and BMF-650, while cutting costs to extend its cash ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results